InSite Vision Regains Development Rights for AzaSite Xtra™ InSite Vision Incorporated today announced that the company has regained North American development rights to azithromycin ophthalmic solution 2%, trademarked as AzaSite Xtra™, from Inspire Pharmaceuticals Inc., a subsidiary of Merck & Co., Inc., known as MSD outside the United States and Canada.
June 21, 2013 - Business Wire via Yahoo! Finance